JAIDS Journal of Acquired Immune Deficiency Syndromes:
Epidemiology and Social Science
The Cost-Effectiveness of Antiretroviral Therapy for Treating HIV Disease in the Caribbean
Wolf, Lindsey L SB*; Ricketts, Paul MD, MSc, DLSHTM†; Freedberg, Kenneth A MD, MSc*‡§∥; Williams-Roberts, Hazel MD¶; Hirschhorn, Lisa R MD, MPH‡; Allen-Ferdinand, Kathleen MD¶; Rodriguez, William R MD‡; Divi, Nomita MSc*; Wong, Michael T MD#; Losina, Elena PhD*‡§
From the *Division of General Medicine and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA; †Ministry of Health, Roseau, Dominica; ‡Division of AIDS and Center for AIDS Research, Harvard Medical School, Boston, MA; §Departments of Epidemiology and Biostatistics, Boston University School of Public Health, Boston, MA; ∥Department of Health Policy and Management, Harvard School of Public Health, Boston, MA; ¶Ministry of Health, Basseterre, Saint Kitts and Nevis; and the #Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, MA.
Received for publication February 21, 2007; accepted August 23, 2007.
Supported by the National Institute of Allergy and Infectious Diseases (grants P30 AI060354, R37 AI42006, K24 AI062476, and K25 AI50436).
All authors contributed to the conception and design of the study. P. Ricketts, H. Williams-Roberts, K. Allen-Ferdinand, W. R. Rodriguez, and M. T. Wong acquired data for the study. L. L. Wolf, K. A. Freedberg, and E. Losina designed the analysis of the data. All authors participated in interpretation of results. L. L. Wolf performed the analysis and drafted the article. All authors revised the article critically for important intellectual content. All authors have given final approval for publication.
Correspondence to: Lindsey L. Wolf, SB, Division of General Medicine, Massachusetts General Hospital, 50 Staniford Street, 9th Floor, Boston, MA 02114 (e-mail: firstname.lastname@example.org).
Background: Antiretroviral therapy (ART) recently became available in the Organization of Eastern Caribbean States (OECS). Survival benefits and budgetary implications associated with universal access to ART have not been examined in the Caribbean.
Methods: Using a state-transition simulation model of HIV with regional data, we projected survival, cost, and cost-effectiveness of treating an HIV-infected cohort. We examined 1 or 2 ART regimens and cotrimoxazole. In sensitivity analysis, we varied HIV natural history and ART efficacy, cost, and switching criteria.
Results: Without treatment, mean survival was 2.30 years (mean baseline CD4 count = 288 cells/μL). One ART regimen with cotrimoxazole when the CD4 count was <350 cells/μL provided an additional 5.86 years of survival benefit compared with no treatment; the incremental cost-effectiveness ratio was $690 per year of life saved (YLS). A second regimen added 1.04 years of survival benefit; the incremental cost-effectiveness ratio was $10,960 per YLS compared with 1 regimen. Results were highly dependent on second-line ART costs. Per-person lifetime costs decreased from $17,020 to $9290 if second-line ART costs decreased to those available internationally, yielding approximately $8 million total savings.
Conclusions: In the OECS, ART is cost-effective by international standards. Reducing second-line ART costs increases cost-effectiveness and affordability. Current funding supports implementing universal access regionally over the next year, but additional funding is required to sustain lifetime care for currently infected persons.
The Organization of Eastern Caribbean States (OECS) includes 9 territories-Anguilla, Antigua and Barbuda, the British Virgin Islands, Dominica, Grenada, Montserrat, St. Kitts and Nevis, St. Lucia, and St. Vincent and the Grenadines-with a total regional population of 609,000; 5000 are estimated to be HIV-infected.1 In 2006, fewer than 800 people were aware of their infection.1 With substantial mobility between OECS nations, the rest of the Caribbean, and Europe and the Americas and economies dependent on tourism, the AIDS epidemic in the OECS may have an inordinate impact regionally. Funding has been awarded to 6 of the OECS territories (Antigua and Barbuda, Dominica, Grenada, St. Lucia, St. Kitts and Nevis, and St. Vincent and the Grenadines) by the Global Fund to Fight AIDS, Tuberculosis, and Malaria to work toward several HIV control measures in the region. Top priorities include the provision of universal access to care and treatment, voluntary counseling and testing services, locally available laboratory monitoring, and antiretroviral therapy (ART) at low cost.1
Beginning in 2004, ART became available through national programs in the OECS. Although first-line ART is currently available at discounted negotiated prices, second-line regimens remain much more expensive. Because ART became available only recently, and the number of patients receiving ART is relatively small (an estimated 266 persons in the OECS in August 2006), there has not yet been a large demand for second-line drugs.2 With an estimated 250,000 persons currently living with HIV/AIDS in the Caribbean and nearly 3000 HIV-infected persons identified since the beginning of the epidemic in the OECS, however, this is likely to change in the near future.2,3
Provision of HIV care in the OECS is largely governed by recommendations from the Caribbean HIV/AIDS Regional Training Network. These recommendations, consistent with those from the World Health Organization (WHO), suggest that ART should be offered to all symptomatic patients and asymptomatic patients with CD4 counts <200 cells/μL.4,5 They also suggest that ART should “generally be offered” to patients who are asymptomatic or have minor symptoms and a CD4 count between 200 and 350 cells/μL. Our objectives were to model the HIV care currently available in the OECS to evaluate clinical outcomes and cost-effectiveness and to assess the budgetary impact of providing universal access to HIV treatment in this region of the Caribbean.
We conducted a model-based analysis incorporating data from the best available sources from different sites in the Caribbean, including OECS countries, Barbados, and Jamaica. We examined 4 main strategies: (1) no treatment (for comparison purposes), (2) treatment with cotrimoxazole prophylaxis alone when the CD4 count was <200 cells/μL, (3) treatment with ART alone (CD4 count <350 cells/μL), and (4) treatment with ART (CD4 count <350 cells/μL) plus cotrimoxazole (CD4 count <200 cells/μL). For strategies that included ART, we considered 2 different cases: only 1 available regimen (or “line”) of ART and the availability of a second-line regimen for use after immunologic (CD4 cell count) or clinical (opportunistic disease diagnosis) failure of first-line therapy. Treatment with ART was initiated at a CD4 count <350 cells/μL in accordance with the recommendations of the Caribbean HIV/AIDS Regional Training Network.4 Cotrimoxazole prophylaxis was initiated at a CD4 count <200 cells/μL based on local practice.6 Although the WHO recommends initiating cotrimoxazole prophylaxis when the CD4 count is <350 cells/μL, this recommendation is targeted at settings with high prevalences of malaria and bacterial infections, which the OECS lacks.7
We assumed that CD4 cell count testing was available for clinical decision making, in addition to clinical diagnoses but that HIV RNA testing was not available, according to the current standard of care in the OECS.4 Clinical assessments occurred every 3 months, and CD4 cell counts were tested every 6 months.4 As recommended by the WHO, first-line therapy was switched to second-line therapy, if available, when the CD4 cell count decreased by 50% from the peak value on treatment or a severe opportunistic disease was observed at least 6 months after ART initiation.5 The last available ART regimen for each patient was continued until death.5 Different strategies for switching and stopping therapy were examined in sensitivity analyses, including using only immunologic information, only clinical information, or both.
The incremental cost-effectiveness ratio-the difference in cost divided by the difference in survival between a given strategy and the “next best” (less expensive but less effective) strategy-was calculated for each strategy. Strategies that were “dominated” by strong dominance (more expensive and less effective than another strategy) or weak dominance (less expensive, less effective, but less cost-effective than another strategy) were excluded.8 We adopted a modified societal perspective, excluding patient time and travel costs, and discounted costs and life years by 3% per year.9
The WHO-sponsored Commission on Macroeconomics and Health has proposed that “cost-effectiveness” be defined in relation to an individual country's per capita gross domestic product (GDP).10 Health interventions with incremental cost-effectiveness ratios <3 times a country's annual GDP would be considered “cost-effective,” and interventions with ratios less than the annual GDP would be “very cost-effective.” In the OECS, annual per capita GDP ranges from $3800 (St. Vincent and the Grenadines) to $11,200 (Antigua and Barbuda).
The Cost-Effectiveness of Preventing AIDS Complications (CEPAC) international model, an adaptation of the published CEPAC US model,11-13 is a state-transition model of HIV disease in resource-limited settings.14-16 In a first-order Monte Carlo simulation, a cohort of patients proceeded through the model, with each patient making monthly transitions among different health states, including chronic HIV, acute complications from an opportunistic disease, and death. These health states were stratified by current CD4 cell count, current HIV RNA level, and history of opportunistic diseases. Opportunistic diseases were divided into 6 groups: Pneumocystis jirovecii pneumonia, Mycobacterium avium complex, toxoplasmosis, cytomegalovirus, fungal infections, and other severe diseases. Death in the model was attributed to chronic HIV, an acute opportunistic disease, or non-HIV-related causes. Other specifications of the model have been previously published (available at: http://content.nejm.org/cgi/data/355/11/1141/DC1/1).14-16
Regionally, the most robust data clinically and demographically consistent with HIV-infected patients in the OECS were from Jamaica. We simulated a cohort of HIV-infected adults using characteristics reported in the Jamaican Ministry of Health HIV/AIDS Tracking System (HATS), a national surveillance database, with a mean age of 36 years and gender distribution 58% male.17 Because CD4 cell counts were not available for patients in the HATS, a baseline CD4 cell count distribution was estimated by matching reported disease stages from the HATS data set (asymptomatic HIV, symptomatic HIV, and AIDS) with CD4 cell count distributions for corresponding WHO stages (stages II, III, and IV) reported from a clinical trial in a resource-limited setting.18 An average of the mean stage-specific CD4 cell counts, weighted by the percentage of patients in each disease stage in the HATS, gave a baseline CD4 count distribution with a mean of 288 cells/μL (SD = 130 cells/μL). We assumed the cohort had an HIV RNA distribution taken from a clinical trial in a similar setting (Table 1).19
Survival Data: Calibration to a National Surveillance Data Set
The best available region-specific survival data from the Caribbean were also from the Jamaican HATS data set.17 We calibrated to obtain baseline estimates for the monthly probability of AIDS-related death in the model, varying the monthly probability of AIDS-related death while keeping all other parameters constant, to match the natural history (untreated) survival output from the model with the observed HATS survival at 1 year (∼80%). This calibration yielded baseline values for the monthly probability of AIDS-related death, stratified by disease stage, that were 7.75 times the values observed in the United States Multicenter AIDS Cohort Study (MACS; see Table 1). Mortality during a month with an opportunistic disease was characterized separately and was assumed to be similar to the rates seen in the MACS.20 Background mortality, stratified by age and gender, was applied from WHO estimates for Jamaica.21 These assumptions were all tested in sensitivity analyses.
Natural History of Disease
Other estimates for the natural history of disease were taken from the MACS (see Table 1).20,21a These data were chosen because the spectrum of opportunistic diseases in the OECS is more similar to that seen in the United States than in many other resource-limited settings.22 Specifically, there is a lower incidence of tuberculosis in the OECS than in other nearby resource-limited settings, such as Haiti.23
Prophylaxis and ART Efficacy
Estimates for cotrimoxazole prophylaxis efficacy were from a published meta-analysis.24 Efficacy of first-line ART was from a cohort study in Barbados, with 80% of patients achieving virologic suppression after 12 months with a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen.25,26 Efficacy of second-line therapy was from a lopinavir/ritonavir-based regimen in treatment-experienced patients with no protease inhibitor mutations at baseline (62% suppression at 12 months).27,28 An additional ART benefit, on top of CD4 cell count increase, was a reduction in morbidity and mortality, as previously reported (see Table 1).29
Costs for ART and cotrimoxazole were from the regional OECS Pharmaceutical Procurement Service and represent the cost of publicly available treatment (F. Burnett, personal communication, September 2006; see Table 1). Standard-of-care first-line therapy includes zidovudine, lamivudine, and nevirapine throughout the OECS.2,4 If available, the most commonly used second-line regimen includes didanosine, abacavir, and lopinavir/ritonavir.2 In sensitivity analyses incorporating the currently available international cost of generic second-line drugs, costs were from the 2006 Médecins Sans Frontières drug pricing report.30 Cost estimates for hospital and outpatient care were from the WHO CHOosing Interventions that are Cost Effective (CHOICE) study, which modeled costs of care in the OECS countries.31,32 Mean regional costs for an inpatient day and outpatient visit were calculated from these data. Because regional estimates for utilization of inpatient and outpatient HIV medical care were not available, published health care utilization rates reported in the United States through the HIV Research Network study were used.33,34 These values were varied widely in sensitivity analyses to assess any potential impact on the results. Cost per opportunistic disease was calculated by multiplying the utilization of outpatient visits by the cost of an outpatient visit and adding the result to the product of number of days of inpatient utilization and cost of an inpatient day (see Table 1). All costs were converted to and reported in 2006 US dollars using country-specific GDP deflators and the fixed exchange rate between the Eastern Caribbean dollar and the US dollar.35,36
Using the CEPAC international model, we calculated national and regional expenditures that would be required to treat currently identified HIV-infected persons in each of the OECS countries and the whole region. Average cost per person for treatment and care was modeled for 1 year and over a lifetime. These costs were multiplied by the estimated number of HIV-infected persons currently identified in the countries to obtain 1-year and lifetime cost estimates for the cohort of currently HIV-infected persons.
The number of HIV-infected persons currently alive and identified in each OECS country was estimated based on the cumulative total of HIV-infected persons reported by the OECS HIV/AIDS Project Unit in 2006.2 We estimated the percent of patients who had died based on cumulative surveillance data from the United States before treatment was available there (315,475 deaths/506,538 AIDS cases [62%]).37 This percentage was applied to estimate that 1768 persons reported with HIV in the OECS had died since the beginning of the epidemic. Remaining persons were assumed to be alive and to represent the number currently identified.
Assuming that those persons identified in each country were similar to the simulated population at model entry, with some requiring treatment based on CD4 count criteria and some not yet requiring treatment, we performed an analysis for 2 different cases: (1) the best practice recommendation for care (2 lines of ART when the CD4 count was <350 cells/μL, with cotrimoxazole when the CD4 count was <200 cells/μL) and (2) the best practice recommendation for care, as already reported, but with generic drug costs currently available in other countries for second-line ART.30
Base Case Analysis
With no treatment, starting with a mean (SD) CD4 count of 288 cells/μL (130 cells/μL) and mean age of 36 years, projected mean per-person survival was 2.30 years, with a lifetime cost of $1600 per person. When we assumed that only 1 line of ART was available, initiating ART when the CD4 count was <350 cells/μL, combined with cotrimoxazole prophylaxis when the CD4 count was <200 cells/μL, mean per-person survival increased to 8.16 years with a lifetime cost of $5620 per person, for an incremental cost-effectiveness ratio of $690 per year of life saved (YLS) compared with no treatment. Compared with the per capita annual GDPs in the region, and using the WHO Commission on Macroeconomics and Health guidelines for cost-effectiveness, treatment using 1 ART regimen with cotrimoxazole may be considered very cost-effective (less than the GDP for all OECS countries; Fig. 1) compared with no treatment. When second-line ART was available, survival increased to 9.20 years at an additional cost of $11,400, and the cost-effectiveness ratio increased to $10,960 per YLS compared with 1 line of ART, which may be considered cost-effective (<3 times the GDP for all OECS countries; see Fig. 1) by international standards (Table 2). Although the cohort spent an average of 1.96 years, or 21% of survival time, on second-line therapy, 68% of lifetime costs were spent on second-line drugs, an average of $11,610 per patient. In contrast, only 12% of lifetime costs were spent on first-line drugs. The remaining 20% of costs were spent on routine medical care, inpatient stays, cotrimoxazole prophylaxis, adverse events, and CD4 cell counts.
Baseline CD4 cell count, rate of CD4 cell decline off therapy, and ART efficacy had the greatest impact on survival outcomes, although because longer or shorter survival incurred greater or fewer costs, these parameters did not have a major influence on cost-effectiveness. Baseline CD4 count was varied from that of a cohort with WHO stage II disease (mean CD4 count = 408 cells/μL) to that of a cohort with stage IV disease (mean CD4 count = 132 cells/μL), resulting in mean life expectancies with treatment with 2 lines of ART varying from 9.83 to 6.39 years. Varying the rate of CD4 cell decline from twice to one half of the base case rate gave life expectancies with 2 lines of ART ranging from 8.14 to 10.39 years. Finally, varying first-line ART efficacy in terms of viral suppression at 6 months from 46% to 94% gave life expectancies ranging from 7.21 to 9.85 years. To test the impact of calibrated mortality rates, we varied the probability of chronic AIDS death, stratified by CD4 cell count, from twice to one half of the base case, which yielded life expectancies ranging from 8.21 to 10.06 years.
The cost of second-line ART and the strategies used to switch therapy had the greatest impact on cost-effectiveness. Decreasing second-line ART cost yielded substantially lower cost-effectiveness ratios. When the cost of second-line ART was decreased to the generic prices recently reported by Médecins Sans Frontières ($172 per month from the base case of $515 per month),30 the incremental cost-effectiveness ratio for 2 lines of ART initiated when the CD4 count was <350 cells/μL with cotrimoxazole decreased to $3530 per YLS (see Fig. 1). At the generic cost for second-line ART, total lifetime costs decreased from the base case result of $17,020 to $9290, with second-line ART costs representing 42% of the total cost of lifetime medical care. Switching from first- to second-line therapy only with an opportunistic disease (removing the criterion of CD4 cell count decrease by 50% from on-treatment peak) decreased survival to 8.17 years from the base case survival of 9.20 years, with a cost-effectiveness ratio of $70,800 per YLS (Table 3).
Budgetary Analysis of Universal Access
To provide lifetime treatment and care to the currently identified 1070 HIV-infected persons living in the OECS with the best practice strategy (2 lines of ART when the CD4 count was <350 cells/μL with cotrimoxazole), $18.2 million would be required region-wide for medical care and drugs, or $2.0 million per year over the mean length of survival of 9.20 years (Table 4). Four percent of that amount (or $685,500) is required over the next year. If second-line drug prices in the OECS were reduced to those currently available for generic second-line drugs elsewhere, the regional estimate for lifetime care cost would decrease by 45%, to $9.9 million, with $678,800 required over the next year (see Table 4).
We used the best available Caribbean data and a published computer simulation model of HIV disease to estimate the survival, cost-effectiveness, and budgetary implications of different strategies for HIV care in the OECS. The most effective strategy included 2 sequential lines of ART, initiated when the CD4 count was <350 cells/μL, with cotrimoxazole when the CD4 count was <200 cells/μL; this strategy was cost-effective throughout the OECS and provided a mean survival gain of 6.90 years per person compared with no treatment. Although this strategy was cost-effective by international standards and consistent with current regional guidelines, the cost of second-line ART comprised 68% of total lifetime care costs, making the 2-line strategy much less affordable than a 1-line strategy. Early initiation of treatment with 1 line of ART provided 89% of the life expectancy achieved with 2 lines of ART at one third of the cost. Projected costs for the complete scale-up of universal lifetime access to treatment to currently identified patients in the OECS were $18.2 million over the next 9 years.
Although there are no published studies on the cost-effectiveness of ART from the Caribbean, several studies have examined the cost-effectiveness of ART in other resource-limited settings.15,38-40 Goldie et al15 reported cost-effectiveness for ART treatment in Côte d'Ivoire that ranged from very cost-effective (less than the GDP) to cost-effective (<3 times the GDP). Two studies from South Africa reported incremental cost-effectiveness ratios that ranged from cost-effective at current ART prices to cost saving at anticipated reduced ART prices.38,39 Paton et al40 reported cost-effectiveness for treatment in Singapore, finding that ART was cost-effective across all stages of HIV infection. The results of the current analysis are consistent with these findings from Africa and Asia.
In March 2005, funding from the Global Fund to Fight AIDS, Tuberculosis, and Malaria began a 5-year effort to develop structure and capacity for treatment of HIV in the OECS, with a project budget of $8.9 million.1,41 According to the current study, although the 1-year cost for providing medical care and drugs to all currently identified HIV-infected persons in the OECS is $685,500, the cost to provide services over the lifetimes of these persons is between $9.9 and $18.2 million over the next 9 years, depending on the price of second-line ART. These forecasted costs do not include costs required to achieve other regional aims, including the expansion of voluntary counseling and testing; capacity for local laboratory monitoring; and capacity building, including infrastructure, new systems, and personnel training or resources needed for newly identified patients through expanded testing. Therefore, this study suggests that although implementation of universal access to treatment for currently identified patients in the OECS may be initiated with current support from the Global Fund to Fight AIDS, Tuberculosis, and Malaria, additional funding is required to sustain lifetime care for currently infected persons. Reducing the cost of second-line ART to the region would substantially lower overall expenditures required to provide universal access to treatment in the OECS.
This analysis has several limitations. There remains a dearth of region-specific data from the Caribbean, especially on CD4 cell counts, HIV RNA levels, and other markers of HIV natural history. Therefore, data for this study were derived from multiple sources. Because of the lack of complete OECS data, including data on short-term mortality from opportunistic diseases and chronic mortality, we calibrated the chronic mortality rate in the model to Jamaican national surveillance data.17 Although the calibrated chronic mortality is quite high compared with mortality in the MACS, this rate may include increased death from opportunistic diseases in the OECS as well as other AIDS-related deaths. Although better estimates for these parameters would give more specific projections for survival and cost-effectiveness, we dealt with the lack of primary data through calibration and sensitivity analyses, finding that the policy conclusions remained robust across a wide range of estimates. It was similarly difficult to find high-quality data on the prevalence of HIV infection in the region and the proportion of those infected who require treatment. The most recently reported results were used; however, as better estimates become available, the lifetime cost results of the current study can be applied to update the budgetary analysis for the region. Finally, the budgetary projections did not account for costs arising from the treatment and care of incident HIV cases, because the model used was not an epidemic model.
Most patients in the Barbados cohort, from which we derived first-line ART efficacy, were initiated on an efavirenz-based regimen with 2 nucleoside reverse transcriptase inhibitors.25,26 Although the current standard of care for first-line ART in the OECS is a nevirapine-based regimen, there is evidence of similar efficacy using either of these NNRTIs.42 Therefore, we applied the efficacy estimate from Barbados, coupled with nevirapine cost, which is used in most cases in the OECS, for the base case. Further, the percentage of patients suppressed in the Barbados cohort was similar to that in other studies, including the Antiretroviral Therapy in Lower Income Countries Collaboration (ART-LINC), the Haitian Study Group for Kaposi's Sarcoma and Opportunistic Infections, and the Médecins Sans Frontières Khayelitsha, South Africa cohort.23,43-45
Much attention has been given to the HIV epidemic in the Caribbean, yet few epidemiologic and clinical research studies have been published from the region, and most of those are from Haiti.23,46 Furthermore, there is a lack of operational and policy research to inform efficient regional HIV policy formation. The compilation of available region-specific data inputs for this analysis highlights the need for increased research in the Caribbean to understand better the natural history of HIV disease, the efficacy of prophylaxis and ART, and the impact on quality of life of HIV disease and its treatment. This analysis shows that the current cost of second-line ART is extremely high and strongly influences the cost-effectiveness and total lifetime cost of adequate HIV care in the Caribbean. Even if currently reported generic drug prices could be obtained in the region, the cost of second-line drugs remains a major component of total costs and may ultimately limit access to effective treatment. Lower drug prices are needed for second-line therapy. At the same time, national programs should distribute less expensive first-line therapy to all who need it and work to increase total funding for treatment in the region, which is going to be required in the near future. The budgetary impact of second-line ART highlights the critical importance of adherence support programs, because maximizing the effectiveness of first-line ART regimens should contribute to sustainable HIV treatment programs. ART for HIV disease in the Caribbean is cost-effective and can be further optimized by obtaining lower cost second-line therapy to make the best use of available resources.
The authors gratefully acknowledge Francis Burnett of the OECS Pharmaceutical Procurement Service for providing current regional drug costs, Dr. Peter Figureoa and the HIV/AIDS surveillance team of the Jamaican Ministry of Health for providing access to surveillance data, and the entire CEPAC team for providing contributions to the analysis and interpretation of data.
1. Global Fund to Fight AIDS, Tuberculosis, and Malaria. Grant proposal: scaling up prevention, care and treatment to combat the HIV/AIDS pandemic in the Organization of Eastern Caribbean States (OECS) sub-region. March 2003. Available at: http://www.theglobalfund.org/search/docs/3MAEH_686_339_full.pdf
. Accessed December 28, 2006.
2. OECS Secretariat. Scaling up prevention, care and treatment to combat the HIV/AIDS pandemic in the Organization of Eastern Caribbean States. Global Fund for HIV/AIDS, Tuberculosis, and Malaria grant number MAE-305-G01-H. Report for the period March 1st 2005 to August 31st 2006. Available at: http://www.oecs.org/Documents/GFATM%20annual%20report.pdf
. Accessed December 27, 2006.
6. Kaplan JE. Diagnosis, treatment, and prevention of selected common HIV-related opportunistic infections in the Caribbean region. Top HIV Med
8. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making
9. Gold MR, Siegel JE, Russell LB, et al, eds. Cost Effectiveness in Health and Medicine
. New York, NY: Oxford University Press; 1996.
10. Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development
. Geneva, Switzerland: World Health Organization; 2001.
11. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med
12. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med
13. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis
14. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. AIDS
15. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings-the case of Côte d'Ivoire. N Engl J Med
16. Walensky RP, Weinstein MC, Yazdanpanah Y, et al. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS
17. Losina E, Figueroa P, Duncan J, et al. HIV morbidity and mortality in Jamaica: analysis of national surveillance data, 1993-2005. Int J Infect Dis
. 2007 Aug 10; [Epub ahead of print].
18. Anglaret X, Chêne G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet
19. Seyler C, Anglaret X, Dakoury-Dogbo N, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antivir Ther
20. Multicenter AIDS Cohort Study. MACS Public Dataset. Release PO
4. Springfield, VA: National Technical Information Service; 1995.
21a. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med
22. Kumar A, Kilaru KR, Forde S, et al. Changing HIV infection-related mortality rate and causes of death among persons with HIV infection before and after the introduction of highly active antiretroviral therapy: analysis of all HIV-related deaths in Barbados, 1997-2005. J Int Assoc Physicians AIDS Care
23. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med
24. Ioannidis JP, Cappelleri JC, Skolnik PR, et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii
prophylactic regimens. Arch Intern Med
25. Kilaru KR, Kumar A, Sippy N, et al. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. HIV Med
26. Kumar A, Kilaru KR, Sippy N, et al. Efficacy of highly active antiretroviral therapy in nonclinical trial setting of a developing Caribbean country. J Acquir Immune Defic Syndr
27. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS
28. Naeger LK, Struble KA. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS
29. Cole SR, Hernan MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol
31. Adam T, Evans DB, Murray CJ. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc
33. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care
34. Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care
. 2005;43(9 Suppl):III40-III52.
38. Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med
39. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa-a primary data analysis. Cost Eff Resour Alloc
40. Paton NI, Chapman CA, Sangeetha S, et al. Cost and cost-effectiveness of antiretroviral therapy for HIV infection in Singapore. Int J STD AIDS
41. Global Fund to Fight AIDS Tuberculosis and Malaria. Progress reports: funds committed and disbursed. Grants in detail. 2007. Available at: http://www.theglobalfund.org/EN/
. Accessed August 3, 2007.
42. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet
43. Dabis F, Balestre E, Braitstein P, et al. Cohort profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol
44. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet
45. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS
46. Deschamps MM, Fitzgerald DW, Pape JW, et al. HIV infection in Haiti: natural history and disease progression. AIDS
antiretroviral therapy; Caribbean; cost-effectiveness; Organization of Eastern Caribbean States
© 2007 Lippincott Williams & Wilkins, Inc.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Highlight selected keywords in the article text.
Data is temporarily unavailable. Please try again soon.